Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HuMax-CD4 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CD4 | EXPERIMENTAL | Open label treatment arm |
| Name | Type | Description |
|---|---|---|
| HuMax-CD4 | BIOLOGICAL | Active treatment |
Inclusion Criteria: * Diagnostic biopsy of non cutaneous T Cell lymphoma with positive phenotype * Relapsed or refractory to minimum of one course of chemotherapy * Study is closed to enrollment.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | - | Undisclosed |
HuMax-CD4 is an investigational monoclonal antibody being studied for the treatment of T cell lymphoma, a type of cancer that affects the immune system's T cells. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
HuMax-CD4 targets the CD4 receptor, a protein found on the surface of T cells. By binding to CD4, the antibody is designed to interfere with the function of malignant T cells in T cell lymphoma, potentially leading to their destruction.
HuMax-CD4 is being developed by Emergent BioSolutions Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol EBS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with T cell lymphoma.
HuMax-CD4 is in Phase 2 clinical development. It has completed one Phase 2 trial, and the drug remains investigational, meaning it has not yet received approval from the U.S. Food and Drug Administration or other regulatory bodies for commercial use.
HuMax-CD4 has been studied in a completed Phase 2 clinical trial registered as NCT00877656, titled 'HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma.' The trial enrolled 21 participants aged 18 years and older with T cell lymphoma and was not blinded or controlled.
HuMax-CD4 is a distinct investigational monoclonal antibody developed by Emergent BioSolutions. No alternative names for this drug have been reported in the available clinical trial information, so it is not known to be identical to any other marketed or investigational agent.